A J Bridges|A K Ho - JoVE Visualize

Showing results (191-200 of 201) with videos related to

Pageof 21

Sort By:

Cancer Chemotherapy and Pharmacology|February 9, 2000

Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenograftsP W Vincent, A J Bridges, D J Dykes, et al.

Annals of Tropical Paediatrics|January 1, 1992

Spotted fever in Hong KongR Y Tseng, A K Ho, C K Li, et al.

Neurology|June 14, 2006

Microglial activation correlates with severity in Huntington disease: a clinical and PET studyN Pavese, A Gerhard, Y F Tai, et al.

Molecular and Cellular Biology|July 13, 2000

Assembly and preferential localization of Nup116p on the cytoplasmic face of the nuclear pore complex by interaction with Nup82pA K Ho, T X Shen, K J Ryan, et al.

Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis|January 1, 1995

Multiple drug classes and hyperosmolarity alter binding of muscarinic drugs to mesothelial cells in vitroJ T Hjelle, A K Ho, M A Miller-Hjelle, et al.

Journal of Medicinal Chemistry|July 21, 2001

Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptorJ B Smaill, H D Showalter, H Zhou, et al.

Journal of Neurochemistry|March 1, 1997

Alpha 1D L-type Ca(2+)-channel currents: inhibition by a beta-adrenergic agonist and pituitary adenylate cyclase-activating polypeptide (PACAP) in rat pinealocytesC L Chik, Q Y Liu, B Li, et al.

Journal of Neurology, Neurosurgery, and Psychiatry|November 20, 2002

Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475A E Rosser, R A Barker, T Harrower, et al.

Neurology|December 25, 2003

Profile of cognitive progression in early Huntington's diseaseA K Ho, B J Sahakian, R G Brown, et al.

Proceedings of the National Academy of Sciences of the United States of America|September 30, 1998

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitorD W Fry, A J Bridges, W A Denny, et al.

Pageof 21

Showing results (191-200 of 201) with videos related to

Sort By:

Pageof 21

Cancer Chemotherapy and Pharmacology|February 9, 2000

Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenograftsP W Vincent, A J Bridges, D J Dykes, et al.

Annals of Tropical Paediatrics|January 1, 1992

Spotted fever in Hong KongR Y Tseng, A K Ho, C K Li, et al.

Neurology|June 14, 2006

Microglial activation correlates with severity in Huntington disease: a clinical and PET studyN Pavese, A Gerhard, Y F Tai, et al.

Molecular and Cellular Biology|July 13, 2000

Assembly and preferential localization of Nup116p on the cytoplasmic face of the nuclear pore complex by interaction with Nup82pA K Ho, T X Shen, K J Ryan, et al.

Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis|January 1, 1995

Multiple drug classes and hyperosmolarity alter binding of muscarinic drugs to mesothelial cells in vitroJ T Hjelle, A K Ho, M A Miller-Hjelle, et al.

Journal of Medicinal Chemistry|July 21, 2001

Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptorJ B Smaill, H D Showalter, H Zhou, et al.

Journal of Neurochemistry|March 1, 1997

Alpha 1D L-type Ca(2+)-channel currents: inhibition by a beta-adrenergic agonist and pituitary adenylate cyclase-activating polypeptide (PACAP) in rat pinealocytesC L Chik, Q Y Liu, B Li, et al.

Journal of Neurology, Neurosurgery, and Psychiatry|November 20, 2002

Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475A E Rosser, R A Barker, T Harrower, et al.

Neurology|December 25, 2003

Profile of cognitive progression in early Huntington's diseaseA K Ho, B J Sahakian, R G Brown, et al.

Proceedings of the National Academy of Sciences of the United States of America|September 30, 1998

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitorD W Fry, A J Bridges, W A Denny, et al.

Pageof 21